3-氨基-6-甲氧基-2-氯吡啶 | 135795-46-9

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氨基-6-甲氧基-2-氯吡啶
• 中文别名: 3-氨基-6-甲氧基-2-溴吡啶；3-氨基-2-溴-6-甲氧基吡啶；2-甲氧基-5-氨基-6-溴吡啶；2-溴-6-甲氧基吡啶-3-胺
• 英文名称: 3-amino-2-bromo-6-methoxypyridine
• 英文别名: 2-bromo-6-methoxypyridin-3-amine；2-bromo-6-methoxy-pyridin-3-ylamine
• CAS: 135795-46-9
• 化学式: C₆H₇BrN₂O
• mdl: MFCD05662394
• 分子量: 203.038
• InChiKey: BUPDRKSRZCMGRP-UHFFFAOYSA-N

物化性质

• 沸点：
  293.9±35.0 °C(Predicted)
• 密度：
  1.622±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-2-bromo-6-methoxypyridine
Synonyms: 2-Bromo-6-methoxypyridin-3-amine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-2-bromo-6-methoxypyridine
CAS number: 135795-46-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7BrN2O
Molecular weight: 203.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-6-甲氧基-2-氯吡啶 在 吡啶 、 bis-triphenylphosphine-palladium(II) chloride 、 氢溴酸 、 sodium hydride 、 溶剂黄146 、 二甲基亚砜 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 氯仿 、 N,N-二甲基甲酰胺 、 xylene 为溶剂， 反应 10.91h， 生成 5,11-dihydro-11-ethyl-5-methyl-2-(4-pyrazolyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
  参考文献：
  名称：

  Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes

  摘要：

  The major cause of viral resistance to the potent human immunodeficiency virus type 1 reverse transcriptase (RT) inhibitor nevirapine is the mutation substituting cysteine for tyrosine-181 in RT (Y181C RT), An evaluation, against Y181C RT, of previously described analogs of nevirapine revealed that the 2-chlorodipyridodiazepinone 16 is an effective inhibitor of this mutant enzyme. The detailed examination of the structure-activity relationship of 2-substituted dipyridodiazepinones presented below shows that combined activity against the wildtype and Y181C enzymes is achieved with aryl substituents at the 2-position of the tricyclic ring system. In addition, the substitution pattern at C-4, N-5, and N-11 of the dipyridodiazepinone ring system optimum for inhibition of both wild-type and Y181C RT is no longer the 4-methyl-11-cyclopropyl substitution preferred against the wild-type enzyme but rather the 5-methyl-11-ethyl (or 11-cyclopropyl) pattern. The more potent 8-substituted dipyridodiazepinones were evaluated against mutant RT enzymes (L100I RT, K103N RT, P236L RT, and E138K RT) that confer resistance to other non-nucleoside RT inhibitors, and compounds 42, 62, and 67, with pyrrolyl, aminophenyl, and aminopyridyl substituents, respectively, at the 2-position, were found to be effective inhibitors of these mutant enzymes also.

  DOI：

  10.1021/jm00024a010
• 作为产物：
  描述：

  5-氨基-2-甲氧基吡啶 在 benzyltrimethylazanium tribroman-2-uide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 3-氨基-6-甲氧基-2-氯吡啶
  参考文献：
  名称：

  1N-alkyl-n-arylpyrimidinamines and derivatives thereof

  摘要：

  本发明提供了新颖的化合物、该化合物及其药物组合物，以及在治疗情感障碍、焦虑、抑郁、创伤后应激障碍、进食障碍、上核性麻痹、肠易激综合征、免疫抑制、阿尔茨海默病、胃肠疾病、厌食症、药物和酒精戒断症状、药物成瘾、炎症性疾病或生育问题中使用这些方法。本发明提供的新型化合物为以下公式的化合物： 其中R1、R3、R4、R5、Z、Y、V、X、X'、J、K、L和M如本文所定义。

  公开号：

  US06342503B1
• 作为试剂：
  描述：

  2-((2-bromo-4-(trifluoromethoxy)phenyl)amino)-5-(trifluoromethyl)nicotinic acid 在 HATU 、 N,N-二异丙基乙胺 、 3-氨基-6-甲氧基-2-氯吡啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以49 %的产率得到2-((2-bromo-4-(trifluoromethoxy)phenyl)amino)-N-(2-bromo-6-methoxypyridin-3-yl)-5-(trifluoromethyl)nicotinamide
  参考文献：
  名称：

  [EN] NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS
  [FR] COMPOSÉS DE 2,3-DIHYDROQUINAZOLINONE CONDENSÉS CONTENANT DE L'AZOTE UTILISÉS EN TANT QU'INHIBITEURS DE NAV1.8

  摘要：

  Small molecule inhibitors of Nav1.8 voltage-gated sodium ion channel, including compounds of formula (I), (II), (III), (IV), and (V) are described. Also described are pharmaceutical compositions containing a compound of formula (I), (II), (III), (IV), and (V) and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, such as pain and pain-associated diseases and cardiovascular diseases, such as atrial fibrillation.

  公开号：

  WO2023238065A1

文献信息

• [EN] HCV NS3 PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTÉASE NS3 DU VHC
  申请人：MERCK SHARP & DOHME

  公开号：WO2014025736A1

  公开（公告）日：2014-02-13

  The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

  这项发明涉及含有螺环结构基团的丙型肝炎病毒（HCV）NS3蛋白酶抑制剂，以及这类化合物的用途和合成。
• Copper-Promoted Sandmeyer Difluoromethylthiolation of Aryl and Heteroaryl Diazonium Salts
  作者：Jiang Wu、Yang Gu、Xuebing Leng、Qilong Shen

  DOI：10.1002/anie.201502113

  日期：2015.6.22

  An efficient copper‐promoted difluoromethylthiolation of aryl and heteroaryl diazonium salts is described. The reaction is conducted under mild reaction conditions and various functional groups were compatible. In addition, reactions of heteroaryl diazonium salts such as pyridyl, quinolinyl, benzothiazolyl, thiophenyl, carbazolyl, and pyrazolyl diazonium salts occurred smoothly to afford the medicinally

  描述了一种有效的铜促进的芳基和杂芳基重氮盐的二氟甲基硫醇化反应。该反应在温和的反应条件下进行，并且各种官能团是相容的。另外，杂芳基重氮盐如吡啶基，喹啉基，苯并噻唑基，噻吩基，咔唑基和吡唑基重氮盐的反应平稳地进行，以提供具有医学重要性的二氟甲基硫代杂芳基。此外，还开发了一种更实用的单锅直接重氮化和二氟甲基硫醇化方案，并将苯胺衍生物转化为二氟甲基硫醇化的芳烃。该方法的实用性通过许多天然产物和药物分子的二氟甲基硫醇化得到证明。
• [EN] 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO<br/>[FR] DERIVES DE 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO-2,3-C PYRIDIN-2-YLMETHYL)PENTAN-2-OLE ET COMPOSES ASSOCIES EN TANT QUE LIGANDS DE GLUCOCORTICOIDES POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES ET DE DIABETE
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2005030213A1

  公开（公告）日：2005-04-07

  Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  式(I A)、(IB)、(IC)和(ID)的化合物，其中R1、R2、R3、R4、R5和R6分别如本文所定义的式(I A)、(IB)、(IC)和(ID)，或其互变异构体、前药、溶剂化合物或盐；含有这些化合物的药物组合物，以及利用这些化合物调节糖皮质激素受体功能的方法，以及利用这些化合物治疗由糖皮质激素受体功能介导或以炎症、过敏或增殖过程为特征的疾病状态或病情的方法。
• TGF BETA R ANTAGONISTS
  申请人：Bristol-Myers Squibb Company

  公开号：US20160176871A1

  公开（公告）日：2016-06-23

  The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

  这项发明通常涉及调节TGFβR-1和TGFβR-2活性的化合物，包含这些化合物的药物组合物以及利用该发明的化合物治疗增殖性疾病和失调凋亡疾病（如癌症）的方法。
• [EN] PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-PYRROLIDINYLE URÉE, THIO-URÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078378A1

  公开（公告）日：2014-05-22

  Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  公式（I）的化合物：或其立体异构体、互变异构体、药用可接受的盐、溶剂合物或前药，其中R1、R2、Ra、Rb、Rc、Rd、X、环B和环C的定义如本文所述，其中环B基团和NH-C(=X)-NH基团处于反式构型，是TrkA激酶的抑制剂，并且可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。